491839-49-7

Basic information

• Product Name: PYRIDINE-2-CARBOXYLIC ACID (4-AMINO-PHENYL)-AMIDE
• Synonyms: PYRIDINE-2-CARBOXYLIC ACID (4-AMINO-PHENYL)-AMIDE;N-(4-Aminophenyl)-2-pyridinecarboxamide
• CAS NO: 491839-49-7
• Molecular Formula: C₁₂H₁₁N₃O
• Molecular Weight: 213.24
• Mol File: 491839-49-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: PYRIDINE-2-CARBOXYLIC ACID (4-AMINO-PHENYL)-AMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: PYRIDINE-2-CARBOXYLIC ACID (4-AMINO-PHENYL)-AMIDE(491839-49-7)
• EPA Substance Registry System: PYRIDINE-2-CARBOXYLIC ACID (4-AMINO-PHENYL)-AMIDE(491839-49-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• HazardClass: IRRITANT
• Hazardous Substances Data: 491839-49-7(Hazardous Substances Data)

Upstream product

• 98-98-6 2-Picolinic acid 
• 100-01-6 4-nitro-aniline 
• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 106-50-3 1,4-phenylenediamine 
• 61349-99-3 pyridine-2-carboxylic acid (4-nitro-phenyl)amide 
• 29745-44-6 pyridine-2-carbonyl chloride 

Downstream Products

• 1372892-90-4 N-(4-((3-chloro-1,4-dioxo-1,4-dihydronaphthalen-2-yl)amino)phenyl)picolinamide 

Relevant articles and documents

AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination-proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseas

ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION

The present invention relates to a compound of formula (I) wherein X1 represents an alkenylene group, a -NH-CO- group, a -CO-NH- group, Y1 represents an aryl group selected from a pyridyl group, a pyrazinyl group or a pyrimidinyl group, X2 represents a -O- group, a-CO-NH- group, a -NH-CO-NH- group, a -OCH2- group, a -NH-CO- group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms or a -SO2-NH- group, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or a -CR1R2R3 group or alternatively X2-Y2 represents a group -CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification. The present invention further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

AMINONAPTHOQUINONE COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR BLOCKING UBIQUITINATION-PROTEASOME SYSTEM IN DISEASES

The invention relates to new compounds with low cytotoxicity for blocking the ubiquitination- proteasome system in diseases. Accordingly, these compounds can be used in treatment of disorders including, but not limited to, cancers, neurodegenerative diseases, inflammatory disorders, autoimmune disorders and metabolic disorders.

Glutamate receptor photomodulators

The present invention relates to the discovery of particular aromatic compounds of formula (1), possessing activity as modulators of metabotropic glutamate receptors (mGIuR) whose modulatory activity on the receptor may be controlled by irradiation with suitable light resulting in the optical control of receptor biological function, to the use of said compounds as a medicament, and to pharmaceutical compositions comprising said compounds of formula (1).

Thiourea inhibitors of herpes viruses. Part 1: Bis-(aryl)thiourea inhibitors of CMV

Bis-(aryl)thioureas were found to be potent and selective inhibitors of cytomegalovirus (CMV) in cultured HFF cells. Of these, the thiazole analogue 38 was investigated as a potential development candidate.